Quick Answer
Neumora Therapeutics, Inc. reported Net Income of -$236.93 million for fiscal year 2025.
Neumora Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net Income | -$236.93M +2.8% |
-$243.79M -3.3% |
-$235.93M -80.2% |
-$130.90M | — |
| Diluted EPS | -$1.45 +5.2% |
-$1.53 +57.9% |
-$3.63 +24.5% |
-$4.81 | — |
| Total Assets | $191.05M -39.7% |
$316.97M -36.1% |
$496.19M +16.4% |
$426.23M | — |
| Cash and Equivalents | $182.53M +28.4% |
$142.15M -62.0% |
$374.04M +55.2% |
$240.94M | — |
| Long-Term Debt | $54.53M | — | — | — | — |
| Stockholders Equity | $103.87M -63.8% |
$287.06M -38.8% |
$469.08M +205.0% |
-$446.85M -37.4% |
-$325.22M |
| R&D Expense | $176.06M -12.4% |
$200.93M +40.8% |
$142.72M +55.6% |
$91.75M | — |
| Operating Income | -$241.16M +8.5% |
-$263.46M -4.5% |
-$252.10M -85.5% |
-$135.87M | — |
| Shares Outstanding | 174.26M +7.8% |
161.71M +1.8% |
158.83M +387.0% |
32.61M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$56.76M | +21.8% | -7.6% |
| Diluted EPS | September 30, 2025 | -$0.35 | +22.2% | -6.1% |
| Total Assets | September 30, 2025 | $177.83M | -49.6% | -20.5% |
| Cash and Equivalents | September 30, 2025 | $129.07M | -53.2% | +3.7% |
| Long-Term Debt | September 30, 2025 | $19.56M | — | +0.6% |
| Stockholders Equity | September 30, 2025 | $132.16M | -58.8% | -27.7% |
| R&D Expense | September 30, 2025 | $40.52M | -33.2% | +4.6% |
| Operating Income | September 30, 2025 | -$57.70M | +24.7% | -6.8% |
- Neumora Therapeutics, Inc. reported Net Income of -$236.93 million for fiscal year 2025.
- Neumora Therapeutics, Inc. showed an increase of +2.8% in Net Income compared to the prior fiscal year.
- Neumora Therapeutics, Inc. reported Diluted EPS of $1.45 per share (loss) for fiscal year 2025.
- Neumora Therapeutics, Inc. showed an increase of +5.2% in Diluted EPS compared to the prior fiscal year.
- Neumora Therapeutics, Inc. reported Total Assets of $191.05 million for fiscal year 2025.
- Neumora Therapeutics, Inc. showed a decrease of -39.7% in Total Assets compared to the prior fiscal year.
- Neumora Therapeutics, Inc. reported Cash and Equivalents of $182.53 million for fiscal year 2025.
- Neumora Therapeutics, Inc. showed an increase of +28.4% in Cash and Equivalents compared to the prior fiscal year.
- Neumora Therapeutics, Inc. reported Long-Term Debt of $54.53 million for fiscal year 2025.
- Neumora Therapeutics, Inc. reported Stockholders Equity of $103.87 million for fiscal year 2025.
- Neumora Therapeutics, Inc. showed a decrease of -63.8% in Stockholders Equity compared to the prior fiscal year.
- Neumora Therapeutics, Inc. reported R&D Expense of $176.06 million for fiscal year 2025.
- Neumora Therapeutics, Inc. showed a decrease of -12.4% in R&D Expense compared to the prior fiscal year.
- Neumora Therapeutics, Inc. reported Operating Income of -$241.16 million for fiscal year 2025.
- Neumora Therapeutics, Inc. showed an increase of +8.5% in Operating Income compared to the prior fiscal year.
- Neumora Therapeutics, Inc. reported Shares Outstanding of 174.26 million shares for fiscal year 2025.
- Neumora Therapeutics, Inc. showed an increase of +7.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: